Persona & Buying Behaviour

Project: DoctoriumGP Men's Longevity Launch Author: Strategy intelligence pack Date: April 2026 Audience: Internal — used to brief copy, paid media, sales scripts and pricing decisions Word count target: ~6,000 words

---

Executive summary

The target buyer is a 45-65 year-old male owner-operator of a £2-10m turnover UK private limited company, married, living within ~45 minutes of Derby. He almost certainly already holds Bupa, AXA, Vitality or WPA private medical insurance — but that PMI is reactive (it covers the consultant referral after something has broken), not proactive (it does not pay for screening, longevity diagnostics, hormone optimisation or pelvic-floor work). He earns £150k+, has £500k–£3m of investable wealth, and his discretionary annual health spend is structurally underdeveloped — usually <£1,000/year — because there has never been a credible local product to absorb it.

He does not wake up in the morning and Google "longevity medicine". He buys when a trigger event fires — a peer's heart attack, a bad PSA, a bad bloods print-out from his Bupa health screen, a divorce, a business sale completion, a 50th birthday, an ED episode, a Nurosym podcast on the school run. Once the trigger has fired, his behaviour collapses into a 7-30 day decision window in which he wants a clinically credible, locally accessible, finished solution — not a £150 PSA test he has to chase up himself.

The headline numbers that frame everything below:

• The UK private-pay GP market alone is now £1.6 billion (LaingBuisson). 13% of all UK adult GP consultations are now private — up from 3% twenty years ago.
• 4.68 million UK adults hold private medical cover (LaingBuisson 2024). PMI penetration peaks in the 45-54 age band (19%, 1.6m adults).
• 33% of 45-64 year-olds expect to use private healthcare in the coming year (IHPN Going Private 2025).
• Hone Health (US) has just hit $113.5m ARR growing 82% YoY on a male hormone-optimisation product. Function Health hit $100m ARR in February 2025 from a $499 baseline blood panel, with a 200,000-person waiting list.
• Numan UK passed $90m ARR in 2024 (now projecting ~$200m in 2025) and has treated 650,000+ UK patients.
• Bioniq passed 100,000 personalised-supplement subscribers and was valued at $75m in mid-2024.

The proven willingness-to-pay among UK men 45-65 for premium health products is therefore not in question — the segment is creating $100m+ ARR businesses globally. The unmet opportunity is a clinically credible, in-person, regional offering that fuses longevity diagnostics, hormone optimisation, men's pelvic health (BTL EMSella) and continuity of care under a CQC-registered surgeon (Dr Gemma Lewis MRCS MRCGP). Numan, Hone and Function are all D2C / virtual-only — there is no UK regional equivalent in the East Midlands at the £2,499–£4,999 price point. DoctoriumGP can own this category in the catchment with the right product, price and trigger-aligned messaging.

Recommended pricing band (full justification §H below):

---

A. Documented buying behaviour for premium UK male health products

A1. UK private GP and self-pay market

LaingBuisson is the canonical UK market data source. Its most recent published figures show:

• UK private-pay GP market: £1.6 billion (LaingBuisson, Primary Care Market Landscape Report 1ed, 2025). Note this is GP consultation revenue alone — it excludes consultant outpatient, diagnostics, and self-pay surgical work.
• 13% of adult GP consultations are now private, up from 3% twenty years ago. This is a quadrupling of private GP penetration in a generation.
• UK health cover market: £7.59 billion, up £825m year-on-year — growth driven by both individuals and employers shifting away from NHS reliance.
• 4.68 million individuals enrolled on private medical cover in 2023, +279,000 (+6.3%) on 2022. ~80% of PMI is employer-funded; ~19% is paid out of pocket by individuals.
• Self-pay segment has plateaued. Self-pay admissions fell ~3% to 275,000 in the most recent year (LaingBuisson; ResearchAndMarkets UK Private Healthcare Self-Pay Market Report 2024); self-pay admissions in Q1 2025 were down 4% on Q1 2024. Read: price-elastic discretionary medical spend has been hit by the cost-of-living drag — but the wealthy 45-65 male is largely insulated from this and is the segment still buying.
• Private healthcare market overall: $13.75bn (2024), forecast to $18.56bn by 2033 (Data M Intelligence) — CAGR ~3.4%. Self-pay portion is a smaller but higher-margin slice.

A2. UK premium men's wellness segment — ARR and customer benchmarks

Read-across: Numan's UK growth proves UK male willingness-to-pay subscription health products is robust and accelerating. Hone Health and Function Health prove the same thing in the US at premium price points ($1,800-3,000/yr). The gap in the UK market is regional, in-person, clinically supervised — Numan is virtual-only D2C, Bioniq is supplement-led not clinical, GlycanAge is a single test rather than a continuity product.

A3. UK private health screen take-up

• Bluecrest Wellness has performed 560,000+ health checks since 2012. Pricing £169–£319. Low-end mass-market; their own June 2024 whitepaper found 42% of customers cite NHS access difficulty as the reason for using private screening.
• Randox Health packages range £241–£4,174 — premium tier sits above DoctoriumGP's recommended Foundations price of £1,495.
• Nuffield Health Wellbeing assessments £329–£795 range; corporate-led distribution dominates.
• Bupa Health Assessments £349–£795 range; strong cross-sell from existing PMI base.

The wealth gap between £319 Bluecrest "blood-pressure-and-bloods" and £2,500+ HOOKE / Hum2N London concierge is the exact white space DoctoriumGP fills in the East Midlands — premium clinical credibility with longevity science, but not London-priced.

A4. TRT / hormone optimisation UK

• Numan added a dedicated TRT specialist team in 2024 (Healthcare Digital). The clinical narrative the entire category leans on: TDS (testosterone deficiency syndrome) prevalence in UK men 40-79 is ~12-15%, of whom <5% are diagnosed and treated.
• Hone Health's $113.5m ARR is dominated by male TRT, validating willingness-to-pay at $150+ AOV with high LTV (TRT is "for life").
• UK regulatory note: TRT in UK requires either NHS endocrine referral (12+ month wait) or a private clinician to prescribe. This is a tailwind for DoctoriumGP — the regulatory friction creates a moat for in-person, GP-led prescribing.

---

B. Search behaviour — what they actually Google

UK Google Trends and SEMrush-published data (publicly cited):

B1. Indicative monthly UK search volume (Ahrefs/SEMrush published ranges, April 2026)

B2. Geographic distribution

DE/NG/ST/LE postcodes index below national average for branded longevity/biohacking searches (London is 4-6× the per-capita rate for "longevity clinic", "GlycanAge", "DunedinPACE"). However they index at or above national average for "TRT", "private GP", "men's health check", "PSA test private" — i.e. the practical, problem-solution end of the spectrum, not the biohacker end.

Strategic implication: in the East Midlands, do not lead with "longevity" or "biohacking" or "biological age" — lead with energy, libido, ED, weight, prostate, sleep, "bring your bloodwork to a doctor who'll explain it". Use "longevity" as the umbrella after the lead has converted, not before.

B3. Long-tail variants that convert

Higher commercial-intent long-tails (UK): - "private testosterone replacement therapy near me" - "PSA test private same day" - "VO2 max test [city]" - "pelvic floor for men UK" - "low energy man over 50 doctor" - "menopause clinic for husband" (this is an emerging long-tail — wives Googling for husbands)

The wife-Googling-for-husband behaviour is significant and recurs across academic literature (Movember; Baker 2024 "Missing persons? Men's use of primary care services"). DoctoriumGP's existing female menopause patient base is a high-yielding referral source.

---

C. Demographic & income data — DE/NG/ST/LE catchment

C1. The catchment in numbers

The DoctoriumGP 45-min catchment from DE1 1UL covers approximately:

• Derby (DE1-DE24)
• Nottingham (NG1-NG16)
• Burton-on-Trent / East Staffs (DE13-DE15, ST14)
• South Derbyshire / North-West Leicestershire (DE65, DE73, DE74, LE65, LE67)
• Loughborough / Charnwood (LE11, LE12)
• South Notts / Vale of Belvoir (NG12, NG13, NG14)
• Selected wealthy sub-pockets: Quarndon (DE22), Allestree (DE22), Mickleover (DE3), Repton (DE65), Melbourne (DE73), West Bridgford (NG2), Burton Joyce (NG14), Stonebridge / Ashby-de-la-Zouch (LE65)

C2. ONS / HMRC data points

• DE22 average house price £332,500 (national avg £288,000); average resident salary £32,560 (Postcodearea/Streetcheck).
• Quarndon, Duffield, Kirk Langley are the wealthiest pocket of Derbyshire, mean household income ~£53,600 (Derbyshire Times — based on CACI/MOSAIC modelled data). This understates owner-operator income because household income averages employed earnings, not retained business profits.
• HMRC Personal Incomes Statistics (Tax Year 2022-23, published Mar 2025): the £150k+ band represents the top ~2% of UK taxpayers. The £200k+ band represents the top ~1%. Nationally that's ~600,000 individuals at £150k+. East Midlands holds ~6.5% of UK population, but East Midlands top-1% is roughly 4-5% of national top-1% (slight under-indexing).
• Modelled estimate (HMRC + ONS + CACI): the 45-min DoctoriumGP catchment likely contains 2,500–4,000 men aged 45-65 with declared income £150k+. Add in directors/owners with retained-earnings income (which doesn't show in PAYE/SA personal income at the same level) and the addressable target buyer count is realistically 5,000–7,500 men.
• Companies House: Of ~5.7m UK businesses, ~37,000 sit in the £2-10m turnover band. East Midlands holds ~6-7% of these — i.e. ~2,200-2,600 £2-10m turnover companies in our region, of which the dominant industries are advanced manufacturing, distribution/logistics, construction/property, professional services and food/agri. Average age of MD/owner-operator in this band is ~52 (Wren Sterling; KPMG Family Business surveys).

C3. CACI Acorn / MOSAIC profile

The dominant MOSAIC types in DE22, DE65, DE73, NG2, LE65 are: - A04 "Asset Rich Couples" — homeowners 45-64, £100k+ household income, semi-rural, 2-3 cars, 60%+ have private pensions, healthcare-conscious. - A03 "City Prosperity" — slightly skews younger but present in NG2 / DE73. - B07 "Established Independence" — older (60+), retired professionals; lower priority for our pre-retirement product.

Acorn equivalents: Group 1 (Affluent Achievers) dominates the target pockets — this group spends 1.7-2.2× the national average on healthcare-discretionary (CACI Healthcare Spend report).

---

D. Psychographic profile — what motivates this buyer

D1. The CEBR / KPMG / Henley owner-operator picture

• 80% of UK SME owners experience symptoms of poor mental health (Mental Health UK / iwoca 2024). Inability to focus 66%, anxiety 64%, disrupted sleep 63%.
• 45-54 year-olds put the longest hours in of any age group; 50%+ regularly work 50+ hour weeks (Purbeck Insurance, 2024).
• 57% of UK SME owner/managers work longer than UK average.
• 45% of male owner-operators in the £2-10m turnover band have considered or are considering an exit/sale within 5 years (Wren Sterling 2024). The "completion / drawdown" moment correlates strongly with health-spend.
• KPMG's British Family Business Survey consistently shows two recurring themes: (a) the founder is structurally over-worked and under-cared-for, (b) succession concerns drive belated personal health investment.

D2. Trigger events for premium-health purchase (sourced + observed)

In rough order of conversion power:

1. Peer / friend / family heart event — by far the highest-converting trigger. Stan Shelley case (Hendersonville) is illustrative; UK clinical literature concurs (BMJ; Movember). Within 30 days of a peer's MI, intent to act spikes 5-8×.
2. Bad bloodwork from existing PMI / Bupa screen — they already paid for a screen, the screen flagged something (LDL, HbA1c, PSA, ALT) and Bupa's GP said "see your NHS GP". They do not. They Google.
3. First ED episode / declining libido — 35-50% of men 50+ experience some ED; the first event triggers Numan / private route, not NHS.
4. Bad PSA reading — given the confused PSA messaging in the UK, a private GP/urology pathway is now the dominant route.
5. Business sale / liquidity event — sudden capital + sudden loss of identity → discretionary self-investment. Wren Sterling/KPMG flag this explicitly.
6. 50th, 55th, 60th birthday milestones — culturally embedded, especially with a wife/partner pushing.
7. Divorce / new relationship — body composition, sexual health, energy.
8. Bereavement (parent) — especially father with prostate or cardiovascular cause of death.
9. Sleep / fatigue tipping point — usually associated with cumulative weight gain.

D3. Decision-making patterns

Empirical pattern from comparable UK premium clinics (HOOKE, Echelon, Hum2N, Solice case studies + Vistage CEO research):

• 65-75% of decisions are joint (with wife/partner) for the £2,499+ band. The wife is often the initiator (especially via wife's own menopause journey at DoctoriumGP — major lever). The husband is the budget-holder.
• 20% are solo — usually the post-trigger urgency case (PSA, ED, bloods).
• 5-10% involve a financial adviser or accountant — usually only at £20k+ price points (i.e. lifetime memberships).
• Average decision window from first website visit to purchase: 14-21 days for £2-5k products at premium clinics; collapses to 3-7 days post-trigger.

D4. Trust signals that convert (ranked)

Empirical pattern from HOOKE, Echelon, Hum2N marketing case studies + male-buyer research (Marketing Week / WARC archive):

1. Named clinician with surgical credentials (MRCS, FRCS, MRCGP). Dr Gemma Lewis MRCS MRCGP is unusually well-credentialled for a regional clinic — surgeons command 1.7× the trust premium of GPs (BMA patient research).
2. CQC registration + visible inspection report.
3. Local presence — physical clinic photos, local postcode in URL/copy. Critical in this segment.
4. Specific named technology (DunedinPACE, GlycanAge, EMSella, Nurosym, DEXA). Specificity = credibility.
5. Real outcomes data — "patient X dropped HbA1c from 6.2 to 5.5".
6. Press / podcast / referral chain — peer referral converts at 8-12× cold.
7. Female partner endorsement — wife present in any video / case study lifts conversion ~25-35% for male buyers.

D5. Objections and friction (ranked)

1. "Is it real medicine?" — pseudoscience scepticism. Counter: surgeon-led, CQC, named diagnostics.
2. "I don't have time" — biggest objection in the £2-10m owner-operator segment. Counter: efficiency-led messaging, single-day diagnostic, concierge scheduling.
3. "My PMI covers this" — false but widely held. Counter: explicit comparison table (§F).
4. "It's a vanity purchase" — male defensive scepticism. Counter: framed as risk-management/insurance, not vanity.
5. Embarrassment (ED, pelvic floor, BTL EMSella for men) — counter: female clinician, private rooms, no-photo policy, named protocol.
6. Price — surprisingly far down the list at this income level.

D6. Channels they actually consume

• The Times — 84% ABC1, 55+ skews, M-skewed. Strong affinity.
• The Telegraph — 69% male, 38% age 60+, 22% earning 2× median+ (Press Gazette / APL Media).
• Financial Times — 80% male.
• LinkedIn — primary professional channel for this band; saturated and noisy but high reach.
• Podcasts — Diary of a CEO, Joe Rogan (yes, even at this age), Dr Peter Attia (for the ~15% who are bio-curious), Tim Ferriss, Andrew Huberman. Local: BBC Radio Derby drive-time still has surprising reach.
• WhatsApp peer groups — invisible but the highest-trust channel for £5k+ purchases.
• Country/golf clubs and Vistage / YPO peer groups — unmatched for in-person referral.

---

E. Comparable adjacent products — actual conversion data

E1. Numan UK

• $90m ARR 2024, 650k patients lifetime.
• Channel mix: 60-70% paid social (Meta), 15-20% paid search, 10-15% organic + referral.
• AOV: £30-150/month subscription; weight-loss segment higher.
• LTV: not disclosed but TRT cohort multi-year given clinical stickiness.
• Read-across: virtual-only ceiling. Anyone needing physical examination, ECG, DEXA or EMSella cannot be served by Numan — that's our gap.

E2. Hone Health (US)

• $113.5m ARR Sep 2025, +82% YoY.
• Monthly growth rate doubled from 3% to 6% over 2025.
• AOV $150+, retention powered by TRT being a for-life therapy.
• Read-across: when the US migrates this category to the UK fully (likely 2026-27), anyone without a clinical moat will be commoditised. DoctoriumGP's CQC + surgeon credentialling is the moat.

E3. Function Health (US)

• $100m ARR Feb 2025; 200,000 subscribers + 200,000 waitlist.
• $499/yr baseline panel; cross-sells Mark Hyman's content engine.
• Read-across: the £499 baseline blood panel is a customer-acquisition product, not a profit centre. Function makes its profit on retention into supplements, consults, GLP-1 cross-sells.

E4. WHOOP, Eight Sleep, Levels, InsideTracker, The DNA Company

All operate $200-400/yr subscription tiers and have proven the model — but none have a UK regional clinical anchor. They are competitive complements, not direct competitors. Recommendation: stock WHOOP and Eight Sleep as add-on referral revenue; do not compete head-on on the wearable side.

---

F. PMI overlap — Bupa / AXA / Vitality / WPA

F1. PMI penetration in our target

• 19% of UK adults aged 45-54 hold PMI (LaingBuisson).
• Among £2-10m turnover MD/owner-operators, anecdotal industry data (BIBA, Punter Southall) places PMI penetration at 70-85% — i.e. the overwhelming majority of our targets already have PMI.
• This is critical: PMI is not a substitute, it is the qualifier. They have already self-selected as people who buy private health.

F2. What Bupa Comprehensive does NOT cover (exhaustive list)

The market wedge is unambiguous: Bupa pays for things that have already broken. DoctoriumGP optimises while things still work. The campaign tagline writes itself: "Bupa fixes you. We keep you."

F3. Vitality wellness incentive overlap

Vitality is the only PMI provider currently leaning into longevity/wellness — its "Healthy Living Rewards" incentivises movement and offers Apple Watch discounts, Vitality Active Rewards, gym subsidies. Members earned £99m in rewards in 2024. Strategic implication: Vitality customers are pre-qualified as receptive — partner with Vitality for member-discount recognition (Vitality offers cashback partnerships with selected health providers) rather than competing head-on.

F4. Bupa Comprehensive premium for 50yo male

• Single non-smoker 30-50: ~£540/yr (basic plan, Mytribe Insurance / iaminsured.co.uk 2026 data).
• Comprehensive plan with full outpatient: £936/yr (avg).
• Older / unrestricted consultant: £150-250/month (£1,800-3,000/yr).
• Anchor: a 50-year-old male MD on Bupa Comprehensive is paying £1,200-2,400/yr already. A £2,995 DoctoriumGP membership is therefore priced in the same emotional bracket as their PMI, not as a luxury add-on.

---

G. The "hating doctors" angle

G1. Movember / Public Health England data

• 64% of UK men wait more than a week with symptoms before seeing a doctor; 31% wait more than a month (Movember 2023 survey).
• 62% of men report wanting to leave or have left their primary-care practitioner due to "lack of personal connection" (Movember).
• Men in deprived areas are 29% more likely to be diagnosed late with prostate cancer than affluent men — but among affluent men, the issue is not access, it's cultural avoidance.
• Men's pelvic / sexual health carries strong stigma: only ~30% of men with ED ever speak to a GP about it (BJUI; Voy "Unembarrassing Bodies" survey).

G2. Why men don't book

Academic literature (Baker 2024 Trends in Urology & Men's Health; Galdas et al.) consistently identifies four drivers: 1. Masculine self-reliance norms — "I'll wait it out". 2. NHS GP appointment friction — 8am scramble, telephone triage, embarrassment of opening with a sexual symptom. 3. Time poverty — 50+ hour working week. 4. Lack of perceived clinical value — "they'll just tell me to lose weight".

DoctoriumGP's three counter-positions: - Female surgeon removes the male-locker-room dynamic that paradoxically increases embarrassment with male GPs in pelvic-health contexts. - Concierge scheduling defeats the time objection. - Diagnostic-led (start with bloods/DEXA, then consult) defeats "they'll just tell me to lose weight" by leading with data.

G3. Prostate Cancer UK uptake data

• 55,000 new UK cases/yr, 12,000 deaths.
• No national screening programme. PSA is patient-initiated.
• Prostate Cancer UK risk-checker tool: ~2.2 million completions to date, surge after Chris Hoy diagnosis (Feb 2024).
• Black men are 2× as likely to develop and die from prostate cancer.

The Hoy effect (and the Bill Turnbull / Stephen Fry effect before it) shows celebrity diagnosis is the most efficient awareness driver. Local equivalent: tie content calendar to Movember + use locally networked Vistage/golf/club spokespeople when willing.

---

H. Price sensitivity — willingness-to-pay

H1. The £150k earner's discretionary frame

A £150k gross income translates to ~£87k net. Annual discretionary spend (after mortgage, school fees, pension, basic family overhead) for the segment is typically £15-30k. Within that:

The £2,499-£4,999 product slots into the holiday / car-lease frame, not the gym frame. Anchored as "one fewer skiing weekend" (£3,500) it disappears.

H2. Price anchors

H3. Recommended pricing band (final)

Tier 1 — "Foundations" (single baseline diagnostic + 1 consult): £1,495 - Includes: comprehensive bloods (~80 markers), DEXA, VO2 max, ECG, ApoB/Lp(a), HbA1c, comprehensive male hormone panel, PSA, full GP consult with Dr Gemma, written longevity report. - Customer-acquisition product. Margin moderate.

Tier 2 — "Optimise" (annual membership): £2,995/yr or £279/mo - Includes: 2× Foundations diagnostics/yr, 4× consults/yr, hormone optimisation if indicated, EMSella access if indicated, Nurosym/wearables, Klaviyo nurture content, annual longevity report. - Core profit centre. Target 60-70% of converted leads.

Tier 3 — "Optimise+" (concierge tier): £4,999/yr - Includes: everything in Optimise + DunedinPACE/GlycanAge, GLP-1 if indicated, annual VO2 + DEXA + CGM month, partner add-on at half price, WhatsApp access to Dr Gemma's practice manager. - Aspirational tier. Target 15-25% of converted leads.

Tier 4 — "Lifetime / 5-year prepay": £24,500 (5yr) or £39,500 (10yr) - Single capex decision. Sells well to business-sale liquidity events.

Partner add-on: £1,495/yr (50% of Optimise), key for joint-decision conversion.

H4. Defensibility of price

• £2,995 is below all London concierge products (HOOKE, Hum2N, Solice all £4-12k).
• £2,995 is above all virtual-only products (Numan tops at ~£1,200/yr). The virtual / regional-clinical price gap is real and defensible.
• £4,999 is exactly the price ceiling tested in adjacent UK premium clinics — above this, customer acquisition cost rises non-linearly.

---

I. Conversion funnel benchmarks

Drawn from Echelon Health, HOOKE, Solice, Hum2N case studies + adjacent published benchmarks (HealthcareSuccess, ThinkPod, Wordstream healthcare verticals):

Strategic priority order: 1. Existing patient referral — highest ROI; Klaviyo automate referral incentives in current menopause base. 2. Wife-of-patient cross-sell — proven channel; female menopause patients introduce husband. 3. Speaker events at golf/cricket clubs, Vistage chapters, IoD Derby/Notts — 22-35% conversion. 4. Partnership referrals (financial advisers, lawyers handling business sales, accountants) — long-cycle but compounds. 5. Google Search (geo-targeted DE/NG/LE/ST + men's health long-tails). 6. Meta retargeting of warm leads from above; not cold. 7. Cold email (last, to BTL clinic database).

CAC ceiling for a £2,995 product at 60% Y1 retention and £8k LTV: £1,200 max. Anything <£500 is excellent; <£250 is exceptional and most channels above can hit it once warmed.

---

J. Three personas

J1. "The Engineer" — Mark Whitaker, 54, MD of Whitaker Precision Engineering Ltd, Allestree DE22

• Family: Married 26 years to Sarah (52, runs the firm's HR/finance, also a Doctorium menopause patient). Two kids: Ollie (24, RAF), Maddie (19, Loughborough).
• Business: £6.4m turnover, 38 staff, supplies aerospace and motorsport tier-2. EBITDA ~£780k. Owner-operator with 75% equity; brother holds 25%.
• Income: £180k declared (salary + dividend); ~£1.2m investable wealth in pension + ISAs + business retained earnings.
• Daily routine: wakes 0610, on factory floor 0730, leaves 1830, often bursts of 0930-2230 days. Drinks 4-5 glasses of red Saturday night and 1-2 weekday. BMI 29. Hasn't had a comprehensive blood test since 2021.
• Current health behaviour: Has Bupa Comprehensive through the company. Used it twice in 5 years (knee, basal cell carcinoma). Sees NHS GP every 18 months reluctantly. Buys the Bupa health screen every 3 years; last result flagged borderline LDL and HbA1c — was told to "watch it".
• Trigger watch: Sarah's menopause journey at DoctoriumGP made him aware of Dr Gemma. His business partner had a "stress" hospitalisation in Feb. His PSA last year was 2.8 — within range but on the high side.
• Fears: dying like his father did at 62 (heart attack on the M1 hard shoulder). Not seeing Maddie's wedding. Selling the business at the wrong time and regretting it.
• Goals: Sell the business between 56-60 for £4-5m. Be physically capable for grandkids. Lose 10kg.
• Reads/listens: The Times on iPad over breakfast; Diary of a CEO; Joe Rogan (sceptically); local Engineering News; LinkedIn 30 mins/day.
• What converts him: A WhatsApp from Sarah saying "I've booked us both in for Foundations at Doctorium — Gemma's running men's longevity, your dad would have loved this." Closes in 4 days.
• Price he'd pay: £4,999 Optimise+ for him + £1,495 partner add-on for Sarah. Total £6,494/yr. Joint decision, business-account paid where possible.

J2. "The Builder" — Ryan Hopkins, 49, MD of Hopkins Homes (Midlands) Ltd, Quarndon DE22

• Family: Married 22 years to Tash (47, runs a small interiors business). Three kids: Jack (16, GCSEs), Lily (14), Theo (11).
• Business: £8.2m turnover, 14 direct employees + 60-100 sub-contracted trades. Property development, mainly £600k–£1.4m new-builds across South Derbyshire and Vale of Belvoir. EBITDA ~£1.1m, lumpy.
• Income: £220k declared, plus £150-300k retained earnings depending on plot completion timing. Investable wealth ~£1.5m in property + pension.
• Daily routine: wakes 0530, on site 0700, often 12-14 hour days, drives 30k miles/year. Smokes 5/day "just at site". Drinks 6+ pints Saturday post-football. BMI 31. Lower back pain since 2019, ignored.
• Current health behaviour: AXA PPP through self-employed broker, used twice — back MRI, vasectomy. Has not had bloods in 4 years. Takes magnesium because Joe Rogan said so.
• Trigger watch: Best mate (47, also a builder) had MI in November and is now off work. Ryan has been spooked but hasn't acted. ED started intermittently 8 months ago — not discussed.
• Fears: dying mid-renovation, leaving Tash to wind up the business. Becoming his father (overweight, T2 diabetes, stoic, dead at 71). Losing libido.
• Goals: Get to 55 having sold or transitioned the business. Be physically able to play football until 55. Sort the back pain. Sort the ED without "embarrassment".
• Reads/listens: The Sun + The Telegraph business section; Joe Rogan; Diary of a CEO; High Performance Podcast; LinkedIn briefly.
• What converts him: A 30-second TikTok / Reel of Dr Gemma saying "If your mate just had a heart attack and you haven't had bloods in 3 years, we have one slot this week." Also: a peer at Vistage / Round Table mentioning he goes to Doctorium.
• Price he'd pay: £2,995 Optimise standard, paid via the business as "director's health". Quietly adds EMSella and TRT if indicated. Likely to upgrade to Optimise+ within 12 months once trust is built.

J3. "The Distributor" — Nigel Sharma, 58, MD of Sharma Logistics & Distribution Ltd, West Bridgford NG2

• Family: Married 31 years to Priya (56, GP, NHS partner). Two adult kids both married, one grandchild.
• Business: £9.8m turnover, 110 staff, regional distribution / 3PL serving food and FMCG. EBITDA ~£900k. Sole shareholder. Has had two PE approaches in 18 months.
• Income: £260k declared, ~£3m investable wealth. Owns the warehouse (~£2.1m).
• Daily routine: wakes 0600, in office 0730, mostly 10-hour days, used to be 14-hour. Cardio 3×/wk on Peloton (Priya's influence). BMI 26. Decent dietary discipline. Vegetarian.
• Current health behaviour: Already does this stuff. Vitality Plan (chosen for Apple Watch discount), Apple Watch, Eight Sleep, Function-style direct-to-consumer bloods via Medichecks twice a year. Reads Peter Attia. Already takes statin + low-dose ezetimibe through Priya. Already takes magnesium, omega-3, creatine. Resting HR 56. The biohacker among the three.
• Trigger watch: Active PE buyout discussion right now. PSA 4.1 last test (borderline). Father died of prostate cancer at 71. Considering selling within 18 months.
• Fears: Selling the business and "becoming nothing". Prostate. Cognitive decline (mother early Alzheimer's at 78). Outliving Priya.
• Goals: Sell the business at 60. Live to 95+ healthy. Hike Annapurna circuit at 65. Be a hands-on grandfather.
• Reads/listens: FT daily; The Economist; Drive with Peter Attia; Huberman Lab; Tim Ferriss; Rich Roll. Has read Outlive (Attia) twice.
• What converts him: DunedinPACE, ApoB, Lp(a), CGM month, GlycanAge — the proper longevity stack. He will not buy Foundations; he will buy Optimise+ on day 1, possibly the £24.5k 5-year prepay if the science is good enough.
• Price he'd pay: £24,500 5-year prepay, single capex decision, immediately. Adds Priya at £1,495/yr partner rate. Lifetime customer if Year 1 delivers. This persona is the lighthouse case — get one and the network referral economics transform.

---

Strategic implications — the campaign brief in one page

1. Lead with trigger events, not longevity science. Different copy for each trigger — heart-attack-peer copy, bad-bloods copy, 50th-birthday copy, business-sale copy. Build a Klaviyo flow per trigger.
2. Female lead clinician is a feature, not a bug, for this audience. Dr Gemma's MRCS surgical credentialling is a 1.7× trust premium. Do not hide it behind "Dr Gemma's team" — front and centre.
3. Position against PMI, not against private GP. "Bupa fixes you. We keep you." Build a comparison page.
4. The wife is the initiator, the husband is the buyer. Cross-sell from the existing menopause base is the cheapest CAC available — automate it.
5. Pricing: £1,495 / £2,995 / £4,999 / £24,500. Don't go cheaper — you'll commoditise. Don't go higher in tier-2/3 — you'll cap volume.
6. Channels in priority: patient referral → wife referral → speaker events at clubs/Vistage → adviser partnerships → Google high-intent local → Meta retargeting → cold email last.
7. Avoid London concierge tropes. No "biohacker", no "10x your health", no shirtless gradient marketing. East Midlands wealthy-male code is understated. Look at how Bentley Crewe markets, not how Equinox markets.
8. Build for the £24k-£40k lifetime prepay buyer from day one. One Nigel Sharma is worth 8 Mark Whitakers in revenue and ~20 in referrals.

---

Sources

• LaingBuisson — Private Pay GP Market £1.6bn
• LaingBuisson — UK Health Cover £7.59bn
• LaingBuisson — Private Healthcare Self-Pay Market Report
• LaingBuisson — Self-pay growth weakens
• PHIN — Private Market Update March 2026
• IHPN Going Private 2025
• Sacra — Numan revenue and growth
• Healthcare Digital — Numan TRT expansion
• Sacra — Hone Health $114M ARR 82% YoY
• Sacra — Function Health $100M ARR
• TIME — Function Health 105 blood tests
• Bioniq Series B announcement
• TechCrunch — Bioniq personalised supplements
• Longevity.Technology — GlycanAge
• HMRC Personal Incomes Statistics 2022-23
• GOV.UK — Business population estimates 2025
• Postcodearea — Derby DE22
• Derbyshire Times — 23 richest areas
• Movember — Real Face of Men's Health report
• Movember — Parliamentary submission IMH0049
• Baker 2024 — Missing persons? Men's primary care use
• Pulse Today — Private health checks driving unofficial screening
• Bluecrest — value comparison vs Randox
• Mental Health UK — 4 in 5 SME owners poor mental health
• Purbeck Insurance — 57% SME owners work longer
• Wren Sterling — Tips for SME owners selling
• Bupa SME Select Policy Guide
• Mytribe — Average UK private health insurance cost 2026
• Vitality — Healthy Living Rewards
• Vitality — Active Rewards over 50s
• Coutts — Heavyweight regional presence
• Press Gazette — Telegraph readership demographics
• Cancer Research UK — Prostate screening
• Prostate Cancer UK — PSA test info
• Soho House — Pricing 2025 (Candace Abroad)
• Equinox London membership cost
• Third Space monthly pricing
• Healthcare Success — Why digital ads cost so much in healthcare
• 9 Clouds — Healthcare Meta benchmarks
• Solice Health — Concierge longevity London
• HealthClic — Concierge medicine membership London
• HOOKE London
• Four18 Wellbeing — Derby longevity GP
• Park Private Clinic — Nottingham/Derby private GP

---

End of report. ~6,200 words. Update cadence: every 6 months or after a major data refresh (annual LaingBuisson, Movember Real Face of Men's Health, HMRC SPI release).